Mahmoud Elsheikh 🩺

YouTube video by NephroMed - Dr. Mahmoud Elsheikh MASTERING CRRT- Clinical Case Scenarios

💥My presentation on CRRT practice:

youtu.be/7mpcvHkAjKQ?...

The Mayo Imaging Classification of ADPKD description (left panel) and imaging examples (right panel) with examples (right panel) of (a, b) subclass 1A and 1E, (c-f) subclass 2A, and (g, h) subclass 2B. Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; TKV, total kidney volume. Reproduced with permission of the copyright holder (Kidney Disease: Improving Global Outcomes) from Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int. 2025;107(suppl 2S):S1-S239. doi:10.1016/j.kint.2024.07.009

Core Curriculum by Craig E. Gordon et al:

Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025
bit.ly/465twwK (FREE)

Thirst, sodium, and the hospitalized child: rethinking hypernatremia - Pediatric Nephrology Pediatric Nephrology -

Thirst, sodium, and the hospitalized child: rethinking hypernatremia
(Editorial Commentary )

I don’t get it — BlueSky feels almost identical to X. The only real difference for me is that I have more control over my feed and can focus on medical content only. My question is: why do so many people who’ve moved to BlueSky still post the same content on X? It seems like double the effort.

Highlights from my talk yesterday on Alport syndrome spectrum of disorders. (since no one posted it, I'll have to do it myself)

Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵

💥Decoding acid base disturbances!🧩🧩

youtu.be/yNHfuLRJh_g?...

𝗧𝗢𝗗𝗔𝗬: ISN KHPWG webinar: "Physical Examination of Arteriovenous Access: from inspection to clinical decision."

🗣️ Polyana Bezerra Mendonça, Jim Escobar Torres
👤 Clemente Sousa
🗓️ November 4
🕓 5 pm CET
🔗 Free registration: http://lite.spr.ly/6...

🎧The Nephrologist’s Perspective in Evaluation and Management of Localized Renal Masses

Gain key insights into nephrology’s role in diagnosing and managing localized renal masses.

🔗 Listen now: bit.ly/3DamjQ9

Foamy podocytes and myelinosomes in a case of Fabry's disease. This patient had positive genetic testing.

#nephsky #pathsky #kidneypath #renal

💥HIV associated TMA!

Join us tomorrow, Nov. 4 @ 3pm ET, for an expert-led KDIGO-@medliveofficial.bsky.social webinar on the KDIGO #IgAN Guideline.

Register: bit.ly/4oxpVO3

Learn about updated treatment strategies, emerging therapies, and key safety considerations to support better care for people living with IgAN.

Nodular, amorphous, acellular mesangial deposits that are pale, eosinophilic, and PAS weakly positive.
For Congo red stain.

10 tips on IS in primary MN🎯

youtu.be/uFmheG-VM_w?...

💥What nephrologist should know about renal pathology!

youtu.be/koYYMcW95Qs?...

My presentation about EULAR 2025 - LN update!
youtu.be/lNrKWE5PGHI?...

💥Dilutional acidosis!🚰

How I consult on cardiorenal syndrome:

• Bump furosemide from 20 to 60 mg bid IV
• Consider rapid resumption of sacubitril/valsartan and empagliflozin. Let's not treat these life saving medications as nephrotoxins.

Skeleton Key Group Case #40: Cosmetic Calcium Author: Nikitha (Niki) Cherayil, MD A. The Stem A middle-aged woman with chronic kidney disease stage 3 in the setting of hypertension and recurrent kidney st

Interesting case from the Skeleton Key Group which just keeps pumping out the #FOAMed

www.renalfellow.org/2025/09/28/s...

🧩PLEX!

🧩Causes of CK elevation!

🎯Myopathy
🎯Vitamin D deficiency
🎯Carnitine deficiency
🎯Reduced renal clearance

💥H2 receptor antagonists are renally excreted but generally prescribed safely, with no dose modification.
Cimetidine is best avoided: it interacts with cytochrome P450 enzymes, causing drug interactions, and falsely elevates SCr through the inhibition of active urinary creatinine secretion.

Renal Cell Carcinoma Subtypes Based on Histology. (A) Clear cell renal cell carcinoma. (B) Papillary renal cell carcinoma. (C) Chromophobe renal cell carcinoma. (D) Oncocytoma. (E) Medullary renal cell carcinoma. Based on information in Williamson SR. Renal cell carcinoma classification: what matters? Diagn Histopathol. 2022;28(6):301-308. doi:10.1016/j.mpdhp.2022.03.004; and Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L. Comprehensive review of chromophobe renal cell carcinoma. Crit Rev Oncol Hematol. 2021:160:103287. doi:10.1016/j.critrevonc.2021.103287

Core Curriculum by Kristen Tillquist, Sandipan Shringi, Anthony Chang, and Susie L. Hu:

The Nephrologist’s Perspective in Evaluation and Management of Localized Renal Masses: Core Curriculum 2025 #OpenAccess

bit.ly/4oG2P8b

Renal tubular epithelial cell cast (Sternheimer-Malbin stain) under 1000x bright field. Pt with nephrotic range proteinuria, suspected GN. Note small lipid droplets on most inferior cell in the cast.

Hello! I’m new to Bluesky and looking to connect with the nephrology community.